Medibank share price on watch amid class action and new data threat

Medibank shares closed in the green yesterday after the ASX 200 health insurer updated the market on its response to the October cyber breach.

Key points
  • The Medibank share price is on watch
  • The ASX 200 insurer has been hit with a class action over the October data breach
  • Yesterday Medibank said it would not make any ransom payments

The Medibank Private Ltd (ASX: MPL) share price is on watch this morning.

This comes as news hits the wires that the S&P/ASX 200 Index (ASX: XJO) health insurer has been hit with a class action over the 12 October data breach.

Yesterday the Medibank share price finished up 0.4% after the company updated the market on its response to the data theft.

The company said the hacker had accessed the name, date of birth, address, phone number and email address of 9.7 million current and former customers along with some of their authorised representatives.

That group includes  5.1 million Medibank customers, 2.8 million AHM customers and 1.8 million international customers.

Medibank said it would not pay any ransom demands.

According to CEO David Koczkar:

Based on the extensive advice we have received from cybercrime experts we believe there is only a limited chance paying a ransom would ensure the return of our customers' data and prevent it from being published.

Today the company faces its first, but perhaps not last, class action over the incident.

This comes alongside news that the hackers have threatened to publish the customer data within 24 hours.

A man sits in casual clothes in front of a computer amid graphic images of data superimposed on the image, as though he is engaged in IT or hacking activities.

Image source: Getty Images

What's happening with the Medibank class action?

The Medibank share price is on watch after Bannister Law Class Actions and Centennial Lawyers reported they will jointly investigate the cyber breach.

In a statement released this morning, Bannister said (courtesy of The Sydney Morning Herald):

We believe the data breach is a betrayal of Medibank Private's customers and a breach of the Privacy Act. Medibank has a duty to keep this kind of information confidential.

The two firms will be investigating Medibank breached their privacy policy and the terms of their contract of the medical insurance which they provided to their customers. The lawyers will also assess whether damages should be paid to Medibank customers as a result of their breaches.

Medibank share price snapshot

The Medibank share price has come under significant pressure since the hacking attack was revealed. Shares are currently down 17.5% in 2022. That compares to an 8.6% year-to-date loss posted by the ASX 200.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A business man wearing a life jacket prepares to jump off a sinking boat
ASX Share Market News

ASX 200 utilities and healthcare shares win the week again

This is the second week in which these traditionally defensive market sectors outperformed.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Mesoblast reports Ryoncil revenue surge and improved cash spend

Mesoblast reported a 44% jump in Ryoncil revenue and a substantial improvement in operating cash spend.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »